A 3-year follow-up of 273 participants (mean age 60 years) of the Austrian Stroke Prevention Study provides first information on the rate, clinical predictors and cognitive consequences of MRI white matter lesions (WML) in elderly individuals without neuropsychiatric disease. Lesion progression was found in 17.9% of individuals over a time period of 3 years. Diastolic blood pressure and early confluent or confluent white matter hyperintensities at baseline were the only significant predictors of white matter hyperintensity progression. Genetic association studies in the setting of the Austrian Stroke Prevention Study provide first evidence for genetic susceptibility factors for progression of WML. We observed associations with the paraoxonase Leu→Met 54 polymorphism and with the M235T polymorphism of the angiotensinogen gene. Lesion progression had no influence on the course of neuropsychologic test performance over the observational period, but the statistical power of this analysis was low.

1.
Pantoni L, Garcia JH: The significance of cerebral white matter abnormalities 100 years after Binswanger’s report. A review. Stroke 1995;26:1293–1301.
2.
Awad IA, Johnson PC, Spetzler RF, Hodak JA: Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke 1986;17:1090–1097.
3.
Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP: MRI white matter hyperintensities. Three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999;53:132–139.
4.
Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Horner S, Bertha G, Lechner H: White matter signal abnormalities in normal individuals: Correlation with carotid ultrasonography, cerebral blood flow measurements and cerebrovascular risk factors. Stroke 1988;19:1285–1288.
5.
Carmelli D, DeCarli C, Swan G, Jack LM, Reed T, Wolf PA, Miller BL: Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998;29:1177–1181.
6.
Schmidt H, Fazekas F, Kostner GM, Schmidt R: Genetic aspects of microangiopathy-related cerebral damage. J Neural Transm 2000;59(suppl):15–21.
7.
Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H: Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentration of naturally occurring antioxidants. Stroke 1996;27:2043–2047.
8.
Griendling KK, Alexander RW: Oxidative stress and cardiovascular disease. Circulation 1997;96:3264–3265.
9.
Mackness MI, Arrol S, Abott CA, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129–135.
10.
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:76.
11.
Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, Kostner GM, Hartung HP: MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms. Three-year follow-up of the Austrian Stroke Prevention Study. Arterioscl Thromb Vasc Biol 2000;20:1811–1816.
12.
Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MM: Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995;26:1329–1333.
13.
Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, Lechner A, Kostner GM: Angiotensinogen polymorphism M235T, carotid atherosclerosis and small vessel disease-related cerebral abnormalities. Hypertension 2001;38:110–115.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.